PharmaShots

JANUARY 27, 2023

Magenta Therapeutics Pauses the P-I/II Study in AML Patients Date: Jan 27, 2023 | Tags: Magenta Therapeutics, MGTA-117, AML, Clinical Trial, P-I/II Ipsen Receives CHMP Negative Opinion for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva Date: Jan 27, 2023 | Tags: Ipsen, Palovarotene, Fibrodysplasia Ossificans Progressiva, Regulatory, CHMP, (..)

FDA 40

FDA Immunization 40

Pharmaceutical Technology

FEBRUARY 22, 2023

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. Both drugs come with a high price tag. To an extent, the challenge here lies in the nature of antibodies, says Contreras.

FDA 104

FDA 104

European Pharmaceutical Review

MARCH 1, 2023

Producing biologics by isolating proteins Biologics like antibodies and other protein-based drugs are produced by living cells such as yeast in large bioreactors. The authors explained that these are commonly used for tagging proteins for study or attaching protein drugs to drug-delivering nanoparticles.

Vaccines 94

Vaccines 94

pharmaphorum

JANUARY 18, 2022

The hope is that they will harness and re-programme natural cellular mechanisms to selectively remove the disease driving proteins from human tissues, working by boosting interactions – gluing – between therapeutically relevant proteins and the machinery used by cells to naturally tag and destroy proteins.

Immunization 52

Immunization 52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based

Immunization 52

Immunization Hospitals Vaccines 52

The Checkup by Singlecare

JANUARY 15, 2023

Aduhelm is a monoclonal antibody that targets amyloid beta, the protein which piles up in the brain and seems to be at the root of the disease. Aduhelm carries a hefty price tag, and it is not appropriate for any other form of dementia, such as dementia with Lewy bodies and vascular dementia. Compare donepezil alternatives.

Dosage 52

Dosage FDA Insurance 52

European Pharmaceutical Review

DECEMBER 27, 2023

Additionally, it was not recommended to use low-dose steroids or allow early administration of tocilizumab, a monoclonal antibody targeting the interleukin-6 (IL-6), in order to reduce and prevent severe CRS. This is in addition to its considerable price tag.

Adverse Reactions 84

Adverse Reactions Immunization Medical Schools Chemotherapy 84